TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07893600: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of Oral Recombinant Human Chymotrypsin Lyophilized Powder in Improving Mucosal Visualization Clarity During Gastroscopy

Sponsor: Healthgen Biotechnology Corp. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07893600 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07893600 Rescue Dossier →